Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome

Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflam...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Front Pharmacol
मुख्य लेखकों: Huarte, Eduardo, Peel, Michael T., Verbist, Katherine, Fay, Brittany L., Bassett, Rachel, Albeituni, Sabrin, Nichols, Kim E., Smith, Paul A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2021
विषय:
Pharmacology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107823/
https://ncbi.nlm.nih.gov/pubmed/33981229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.650295
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन